In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

In May, the German group that pioneered the treatment in rheumatic disease reported on a troubling syndrome they dubbed ...

A new study finds that experiences of discrimination are associated with worse patient-reported lupus-related symptoms and depressive symptoms among people with systemic lupus erythematosus (SLE).

Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs ...

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

The study has a two-part, placebo-controlled, double-blind, randomised, dose-escalation (single ascending dose) design.

Background Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric systemic lupus ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE). The drug’s ...